Lilly’s Kisunla (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic…
The Ministry of Health, Labour and Welfare Japan has approved Kisunla (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's Alzheimer's…
Read More...
Read More...